Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
For thou convenience $FNAT BarChart Technical Analysis NITE-LYNX
http://www.barchart.com/technicals/stocks/FNAT
This index can be used as it is, but it is better to approximate it with the help of Moving Average. Approximation with the help a short moving average (the author proposes to use 2 intervals) contributes to finding the best opportunity to open and close positions.
BarChart Technical Analysis NITE-LYNX $RIGH
http://www.barchart.com/technicals/stocks/RIGH
The 125-day Rate-of-Change is the second long-term indicator. This is a simple indicator that measures the percentage price change over the last 125 days, which is around six months. Strong stocks will show the largest gains, while weak stocks will show the largest losses. It is a straight-forward indicator designed to measure pure strength or weakness.
BarChart Technical Analysis NITE-LYNX $APRU
http://www.barchart.com/technicals/stocks/APRU
Traders are often inclined to use Bollinger Bands with other indicators to confirm price action. In particular, the use of an oscillator like Bollinger Bands will often be coupled with a non-oscillator indicator like chart patterns or a trendline. If these indicators confirm the recommendation of the Bollinger Bands, the trader will have greater conviction that the bands are predicting correct price action in relation to market volatility.
Behold the $ELTP BarChart Technical Analysis NITE-LYNX
http://www.barchart.com/technicals/stocks/ELTP
Signal line crossovers are the most common TRIX signals. The signal line is a 9-day EMA of the TRIX. As a moving average of the indicator, it trails TRIX and makes it easier to spot turns. A bullish crossover occurs when TRIX turns up and crosses above the signal line. A bearish crossover occurs when TRIX turns down and crosses below the signal line. Crossovers can last a few days or a few weeks, it all depends on the strength of the move. Due diligence is required before relying on these frequent signals. Volatility in the underlying security can also increase the number of crossovers.
RS values are smoothed after the first calculation. Average Loss equals the sum of the losses divided by 14 for the first calculation. Subsequent calculations multiply the prior value by 13, add the most recent value and then divide the total by 14. This creates a smoothing affect. The same applies to Average Gain. Because of this smoothing.
SCIE going to explode any day now! Get in while you can!
$MVTG do not forget them, they are still closing on replacing hydrogen fuel cells with liquid energy dense formate fuel powered fuel cells using formates made from solar power and carbon dioxide in electrolytic reactors!!!
#CO2 #Emissions $GEVO #Fuels #CleanEnergy #Power
$GEVO - Praj-Gevo Joint Development & Commercialization Phase https://www.reuters.com/article/brief-praj-gevo-joint-development-agreem-idUSFWN1KG0NO
$PPPMF Primero Mining Corp. is a Canadian-based precious metals producer that owns 100% of the San Dimas gold-silver mine and the Cerro del Gallo gold-silver-copper development project in Mexico. Primero's website is www.primeromining.com.
Under the Radar $USLG will move back to previous highs on any news/volume. Legitimate, reporting, LED mfg co with superior technology. Sold at Home Depot.See Post Here for Details.
$CSOC: COMPANY TWEET LAUDING PROGRESS
https://twitter.com/CSOCusa/status/922257277154877440
SRMX... Watch for multiple PR's starting this week... Gonna run...
$ AMFE **
96% buy!!
https://www.barchart.com/stocks/quotes/AMFE/opinion
There is not a Road Block for Buying AMFE.
Fiscal Q1 2018 Revenues up 20,619% Year Over Year to $5,900,346 Setting A New Quarterly Financial Record For The Company
Price can't go down..but it can go up!!
4th straight quarterly profit with each one being higher than the last.
Financial Backing already signed for 50 new Franchised Game Board Cafe's.
AMFE is even safer to buy than APPLE or GOOGLE.
Guaranteed growth.
Never have to check on the PPS or never have to post on the board.
Never have to worry when You own shares of AMFE.
Safest Stock I have ever encountered.
Soon to be named to the OTCQB or OTCQX
Another BIG Press Release Today!!
You haven't heard[seen] nothing yet!!
$MVTG soared on news of a huge jump in revenue friday, in the 10-Q, the rally has just started!!!
AMFE show me another penny that is doing millions in rev each quarter, growing exponentially and profitable. Few exist here in OTC pennyland.
TGGI BULL RUSH COMING FIRST THING TOMORROW. GET IN WHILE YOU CAN.
HUGE TWITTER UPDATE FRIDAY. TO BEGIN RAISING CAPITAL FROM 4 DIFFERENT REVENUE STREAMS! NEWS THIS WEEK! SEE BELOW:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135578699
$PMCB PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight Cancer PMCB
http://www.businesswire.com/news/home/20171017005486/en/PharmaCyte-Biotech-Research-Identifies-Enzyme-Activity-Cannabinoid-Based
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its research partner, the University of Northern Colorado (UNC), has identified an organism whose genome contains the genetic code for production of an enzyme capable of activating a cannabinoid prodrug into its active cancer-killing form.
“We are pleased that UNC has taken us one step closer to developing cannabinoid-based therapies to combat cancer utilizing our proprietary Cell-in-a-Box® live-cell encapsulation technology”
Tweet this
“We are pleased that UNC has taken us one step closer to developing cannabinoid-based therapies to combat cancer utilizing our proprietary Cell-in-a-Box® live-cell encapsulation technology,” commented PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner. “PharmaCyte’s innovative Cannabis Program has established PharmaCyte as a serious player in the medical Cannabis sector, and we are exploring additional strategic relationships to advance product development and commercialization.”
PharmaCyte’s Cannabis Program has had two primary areas of focus. The first is confirming the anti-cancer activity of cannabinoids (constituents of the Cannabis plant), such as tetrahydrocannabinol (THC) and cannabidiol (CBD). UNC’s research has confirmed that a purified cannabinoid showed a potent dose-dependent decrease in cell viability for various cancers, suggesting that this cannabinoid exhibits significant anti-proliferative effects (stops the growth of cancer cells). This activity has been demonstrated in glioblastoma (brain), pancreatic, breast, lung, colon and melanoma cancer cell lines.
The second area of focus is in finding an enzyme capable of converting an inactive, side-effect-free, cannabinoid prodrug into its active cancer-killing form. The research team at UNC has screened numerous cell lines and numerous enzymes. As result of this extensive work, an organism has been identified that has been confirmed to produce an enzyme capable of catalyzing the desired cannabinoid-prodrug-activating reaction. Work is now underway to locate the enzyme’s gene.
Dr. Mark L. Rabe, PharmaCyte’s Director of Cannabis Program Development, commented, “Our work at UNC continues to bear fruit. The work with cancer cell lines not only confirmed cannabinoid anti-cancer activity, it generated important dosing data. The work to identify the needed activating enzyme has been intensive and time-consuming, and we are pleased to have identified a front-running candidate that has exhibited the desired activity.”
Once the location of the activating enzyme gene has been determined within the organism’s genome, a series of steps will occur to amplify and clone the gene and confirm its activity. The gene will then be used to bio-engineer a human cell line that will then become a cannabinoid-prodrug-activating enzyme “factory.” Importantly, the parental human cell line that will be utilized is the same cell line being utilized in PharmaCyte’s therapy for pancreatic cancer. Upon confirmation of the desired activity by the bio-engineered cell line, the final steps include live-cell encapsulation with the Cell-in-a-Box® technology and validation.
Clinically, targeted cannabinoid-based chemotherapy would be accomplished by implanting the encapsulated bio-engineered cells near the site of a tumor, along with administration of a cannabinoid prodrug which would become activated at the site of the tumor by an enzyme produced by the encapsulated cells. The end goal is better efficacy than existing therapies with few, if any, side effects.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.
PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no treatment related side effects.
PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.
Safe Harbor
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement because of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements due to the impact of numerous risk factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
More information about PharmaCyte Biotech can be found at www.PharmaCyte.com. Information may also be obtained by contacting PharmaCyte’s Investor Relations Department.
Contacts
Investor Relations:
PharmaCyte Biotech, Inc.
Dr. Gerald W. Crabtree
Investor Relations Department
917.595.2856
Info@PharmaCyte.com
* * $BTCS Video Chart 10-20-17 * *
Link to Video - click here to watch the technical chart video
* * $PLUG Video Chart 10-20-17 * *
Link to Video - click here to watch the technical chart video
* * $ENRJ Video Chart 10-20-17 * *
Link to Video - click here to watch the technical chart video
* * $BIOA Video Chart 10-20-17 * *
Link to Video - click here to watch the technical chart video
* * $NAK Video Chart 10-20-17 * *
Link to Video - click here to watch the technical chart video
* * $TRXC Video Chart 10-20-17 * *
Link to Video - click here to watch the technical chart video
* * $DXTR Video Chart 10-20-17 * *
Link to Video - click here to watch the technical chart video
AMFE Q1 revenues up over 20,000%! Company did $6MM in Q1 alone basically matching all the revenue from last year in total. They will be uplisting by end of month.
https://www.otcmarkets.com/stock/AMFE/news/Amfil-Technologies-Inc--Announces-Fiscal-Q1-2018-Revenues-up-20-619--Year-Over-Year-to--5-900-346-Setting-A-New-Quarterly-Financial-Record-For-The-Company?id=172992&b=y
* * $DRRX Video Chart 10-20-17 * *
Link to Video - click here to watch the technical chart video
* * $DRYS Video Chart 10-20-17 * *
Link to Video - click here to watch the technical chart video
* * $INPX Video Chart 10-20-17 * *
Link to Video - click here to watch the technical chart video
* * $ONVO Video Chart 10-20-17 * *
Link to Video - click here to watch the technical chart video
BIOPHARMA AEPP/ONCOLIX LOW FLOAT ONLY 33,311,633!!!
PER OTCMARKETS.COM!!!_https://www.otcmarkets.com/stock/AEPP/profile
BIOPHARMA AEPP/ONCOLIX LOW O/S IS ONLY 93,231,633!!!
AS_OF_9/1/17_PER_OTCMARKETS.COM_https://www.otcmarkets.com/stock/AEPP/profile
AEPP/ONCOLIX IS A CERVICAL/BREAST CANCER DRUG_COMPANY
Marijuana season soon: http://investorshub.advfn.com/boards/board.aspx?board_id=31940
$BDGN CHART UPDATE! 22M float and no dilution!
Reversal in effect to break mew highs and MFI - Money Flow Index increasing ready to break .14 and then fly to break .20 this week. Since we broke .10 on Friday at the close the only left was .108 then .12 with Puma with 5k then nothing on L2 to .30 with only 7,500 showing with CDEL and CANT.
Another BULLISH FLAG!
BIGGEST 5 YEAR CUP and HANDLE EVER!
JOIN STOCKGOODIE SKYPE CHAT ROOM! (FREE of Course)
Contact Request: stockgoodies_skyperoom
http://www.stockgoodies.com/stock-chat.html
LVVV legit MJ company. Float of 450 million and had 4 Green Day’s last week. Looks like she is priming for run. Recent news too!
DOLV looking good for this week.
Under the Radar USLG will move back to previous highs on any news/volume. Legitimate, reporting, LED mfg co with superior technology. Sold at Home Depot.See Post Here for Details.
Followers
|
3286
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2804248
|
Created
|
08/22/10
|
Type
|
Free
|
Moderator Nilbud | |||
Assistants mick ManicTrader PhotoChick Kirimi $Pistol Pete$ |
![]() ![]() ![]() UPDATE; 5-1-22 courtesy of charting /\ wit tweezer top calls /\ Tony @Montana_Trades Really good study sheet on Candlestick Patterns [-chart]pbs.twimg.com/media/FRn8188XMAAdZvk?format=jpg&name=small[/chart] ![]()
![]()
02-07-2021
|
Posts Today
|
0
|
Posts (Total)
|
2804248
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |